MorphoSys AG (ETR:MOR) has been assigned a €55.00 ($65.48) price target by Goldman Sachs Group, Inc. (The) in a research note issued to investors on Thursday. The brokerage presently has a “neutral” rating on the stock.

A number of other equities research analysts have also recently issued reports on MOR. Berenberg Bank set a €68.00 ($80.95) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, May 25th. Independent Research GmbH set a €77.00 ($91.67) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Monday, May 29th. Commerzbank Ag set a €76.00 ($90.48) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Tuesday, May 30th. HSBC Holdings plc set a €59.00 ($70.24) target price on shares of MorphoSys AG and gave the stock a “neutral” rating in a research report on Friday, July 14th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of MorphoSys AG in a research report on Monday, July 17th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. MorphoSys AG presently has an average rating of “Buy” and a consensus target price of €70.38 ($83.78).

MorphoSys AG (ETR:MOR) traded down 0.76% on Thursday, reaching €65.25. 4,295 shares of the company’s stock were exchanged. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €70.90. The firm has a 50-day moving average of €60.15 and a 200-day moving average of €59.03. The firm’s market capitalization is €1.89 billion.

ILLEGAL ACTIVITY WARNING: “MorphoSys AG (MOR) Given a €55.00 Price Target by Goldman Sachs Group, Inc. (The) Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/10/morphosys-ag-mor-given-a-55-00-price-target-by-goldman-sachs-group-inc-the-analysts.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.